EPIDEMIOLOGICAL SCIENCE

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Jeffrey A Sparks [1,2] Zachary S Wallace,[2,3] Andrea M Seet,[4] Milena A Gianfrancesco,[4] Zara Izadi,[5] Kimme L Hyrich [6,7] Anja Strangfeld [8] Laure Gossec [9,10] Loreto Carmona [11] Elsa F Mateus,[12,13] Saskia Lawson-Tovey [14,15] Laura Trupin,[4] Stephanie Rush,[4] Patricia Katz,[4] Gabriela Schmajuk,[4,16] Lindsay Jacobsohn,[4] Leanna Wise,[17] Emily L Gilbert,[18] Ali Duarte-García [19] Maria O Valenzuela-Almada,[20] Guillermo J Pons-Estel [21] Carolina A Isnardi,[21] Guillermo A Berbotto,[22] Tiffany Y -T Hsu [23] Kristin M D'Silva [3] Naomi J Patel,[3] Lianne Kearsley-Fleet [6] Martin Schäfer,[8] Sandra Lúcia Euzébio Ribeiro [24] Samar Al Emadi,[25] Liselotte Tidblad,[26] Carlo Alberto Scirè [27] Bernd Raffeiner,[28] Thierry Thomas,[29] René-Marc Flipo,[30] Jérôme Avouac,[31] Raphaèle Seror,[32] Miguel Bernardes,[33,34] Maria Margarida Cunha,[35] Rebecca Hasseli [36] Hendrik Schulze-Koops [37] Ulf Müller-Ladner,[36] Christof Specker [38] Viviane Angelina de Souza,[39] Licia Maria Henrique da Mota [40] Ana Paula Monteiro Gomides [41] Philippe Dieudé [42] Elena Nikiphorou [43] Vanessa L Kronzer [44] Namrata Singh [45] Manuel F Ugarte-Gil [46,47] Beth Wallace,[48,49] Akpabio Akpabio [50] Ranjeny Thomas [51] Suleman Bhana,[52] Wendy Costello,[53] Rebecca Grainger,[54] Jonathan S Hausmann [55,56] Jean W Liew,[57] Emily Sirotich [58,59] Paul Sufka,[60] Philip C Robinson [61,62] Pedro M Machado [63,64] Jinoos Yazdany,[4] COVID-19 Global Rheumatology Alliance

Check for updates

ABSTRACT

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).

Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders.

Results Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity.

Conclusions People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

INTRODUCTION

The ongoing COVID-19 pandemic has had a significant impact on people with rheumatoid arthritis (RA), many of whom are treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).[1] While b/tsDMARDs are important for controlling RA disease activity, their influence on COVID-19 outcomes in people with RA remains unclear. This uncertainty has led to anxiety, social isolation due to shielding practices and b/tsDMARD discontinuation, which may contribute to RA flares.[2–4] Addressing the knowledge gaps around the influence of b/tsDMARDs on COVID-19 outcomes is a priority for people with RA and their providers.

Key messages

What is already known about this subject?
► A previous international registry study of the COVID-19 Global Rheumatology Alliance (C19-GRA) suggested that people with systemic rheumatic diseases on biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) had lower odds of hospitalisation than those not using DMARDs.
► Previous studies reported that people with systemic rheumatic diseases using rituximab had higher odds of COVID-19-related mortality than those using alternative DMARDs such as methotrexate.

What does this study add?
► Using the C19-GRA, we analysed people with rheumatoid arthritis (RA) using b/tsDMARD (to limit the potential for confounding) at the time of COVID-19 onset and investigated an ordinal outcome that encompassed a range of COVID-19 outcomes.
► People with RA using rituximab or Janus kinase (JAK) inhibitors at COVID-19 onset were more likely to experience poor COVID-19 outcomes, ranging from hospitalisation to death, compared with use of tumour necrosis factor inhibitors.

How might this impact on clinical practice or future developments?
► People using rituximab or JAK inhibitors for RA are more likely to experience poor COVID-19 outcomes and should be prioritised for risk mitigation strategies.

The impact of b/tsDMARDs on COVID-19 outcomes is of particular interest since some of these medications, such as tocilizumab and baricitinib, have been studied as repurposed treatments for COVID-19. Some evidence suggests that baseline use of certain b/tsDMARDs, like tumour necrosis factor inhibitors (TNFi), for inflammatory disorders may be associated with less severe COVID-19 outcomes.[5] In addition, among patients with COVID-19, treatment with interleukin 6 inhibitors (IL-6i) and baricitinib led to improved outcomes in some clinical trials.[6–9] However, there are also concerns that baseline use of certain b/tsDMARDs, such as rituximab or abatacept, may be associated with worse COVID-19 outcomes due to impaired viral immune defences.[10 11]

Due to sample size limitations, previous studies of b/tsDMARD use and COVID-19 outcomes have combined heterogeneous rheumatic diseases and medications and/or investigated a single outcome, such as hospitalisation.[5 12] Therefore, we used the COVID-19 Global Rheumatology Alliance (C19-GRA) physician registry to evaluate the associations of different classes of b/tsDMARDs with a range of COVID-19 outcomes in people with RA.

METHODS
Data source and study sample assembly
People with rheumatic disease and COVID-19 from the C19-GRA registry and the European Alliance of Associations for Rheumatology (EULAR) COVID-19 database were included in the analyses. We included cases entered between 24 March 2020 and 12 April 2021. The C19-GRA and EULAR databases include people with rheumatic diseases diagnosed with COVID-19, as reported by rheumatology providers via two international data entry portals. The details of these registries have been previously reported.[5 12–17] We analysed people with RA on b/tsDMARD at the time of COVID-19 clinical onset. As of 12 April 2021, a total of 15 127 people with rheumatic diseases and COVID-19 have been reported. We included people with RA who were taking one of the following medication classes: Cytotoxic T lymphocyte-associated antigen immunoglobulin (CTLA4-Ig: abatacept), anti-CD20 (rituximab), IL-6i (tocilizumab, sarilumab), Janus kinase inhibitors (JAKi: tofacitinib, baricitinib or upadacitinib) or TNFi (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab). The drug class of b/tsDMARD was collected, rather than individual drugs. We did not include IL-1 inhibitors since these were infrequently used for RA. Prior studies using the C19-GRA and EULAR databases have included some patients also reported in this study, but the analyses included in this study and observations reported are novel. In addition, follow-up for this study is more current than previous publications using these data.

Data quality was assessed by the University of California, San Francisco and the University of Manchester, UK, which both confirmed that there were no duplicates in the data entries.

Baseline b/tsDMARD exposures
The exposure of interest was baseline use of a b/tsDMARD at the time of COVID-19 clinical onset. As in previous C19-GRA investigations, we included confirmed and presumptive cases of COVID-19.[5 12 14] We limited this analysis to users of abatacept, rituximab, IL-6i, JAKi or TNFi to limit the cohort to people with similar RA disease severity and minimise the impact of confounding by indication. We included b/tsDMARD users regardless of whether they also used a conventional synthetic (cs) DMARD or glucocorticoids, but did not include people on csDMARDs (eg, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide) monotherapy, as monotherapy may indicate less severe RA or be due to care access barriers or socioeconomic factors. TNFi users were the reference group since TNFis are the most frequently used b/tsDMARD in RA. People with RA who were reported to be on more than one b/tsDMARD were excluded from the analysis.

COVID-19 outcomes
The primary outcome of interest was a mutually exclusive ordinal COVID-19 severity outcome: (1) no hospitalisation, (2) hospitalisation with no oxygenation, (3) hospitalisation with any oxygenation or mechanical ventilation, and (4) death. We chose this primary outcome to estimate the association of b/tsDMARD exposure with general odds of worse COVID-19 severity rather than a single outcome. A similar outcome was developed by the WHO to capture the spectrum of disease and is used in clinical trials evaluating COVID-19 therapeutics.[18] If a patient met multiple levels of the outcome, they were only included at the highest level. At the time of analysis, all patients were required to have a resolved clinical course.

Covariates
Details regarding demographics, including age, race/ethnicity and continent, and patient characteristics, including obesity, smoking, comorbidities (interstitial lung disease (ILD), history of cancer, hypertension, cardiovascular disease, chronic kidney disease/end-stage kidney disease, diabetes, non-ILD pulmonary disease), RA disease activity (as judged by the reporting physician), glucocorticoid dose for RA at the time of COVID-19 onset

and use of concomitant csDMARD (methotrexate, sulfasalazine, hydroxychloroquine), were by physician report. For glucocorticoid dose, the amount of prednisone-equivalent glucocorticoid prescribed was treated as a categorical variable (none, >0–5 mg/day, 6–9 mg/day and ≥10 mg/day). Hypertension and cardiovascular disease were collapsed as a single comorbidity due to collinearity.

Statistical analysis

We reported baseline characteristics and outcomes across the exposure categories of baseline b/tsDMARD use with descriptive statistics.

Ordinal logistic regression models were used to assess the association between each b/tsDMARD compared with TNFi use and the severity of COVID-19 on an ordinal scale in unadjusted and multivariable analyses to estimate ORs and 95% CIs. The effect size of the ordinal outcome can be interpreted as the odds of being one level higher on the ordinal COVID-19 severity scale than the reference group. We assessed the proportional odds assumption for the ordinal regression model using the Brant test.[19] Models in which the proportional odds assumption was not met were refitted using the partial proportional odds model which relaxes the assumption of proportionality for offending predictors.[20] We considered potential confounders known to be associated with either b/tsDMARD use or COVID-19 severity. Covariates included in multivariable models included sociodemographic features (age, sex), obesity, smoking status (ever vs never), concomitant csDMARD use (methotrexate, hydroxychloroquine, sulfasalazine, or leflunomide), categorical glucocorticoid use/dose, categorical comorbidity count (0, 1, 2 of the following: chronic kidney insufficiency/end-stage kidney disease, diabetes, non-ILD pulmonary disease), other key comorbidities as individual variables (hypertension/cardiovascular disease, ILD and cancer), disease activity (moderate/high vs remission/low), continent (Europe, North America, South America, other) and calendar time (January–15 June 2020 vs 16 June 2020–12 April 2021).[21] These time periods were selected based on the initial publication of the RECOVERY trial, which reported a survival benefit associated with dexamethasone and influenced subsequent practice.[22] We assumed that missing data were 'missing at random'. We then performed multiple imputation five times to get pooled estimates to impute missing values for disease activity, race/ethnicity, glucocorticoid dose, smoking, hypertension/cardiovascular disease and comorbidity count. After imputation, we compared the distribution of imputed values with the distribution of variables before imputation to confirm that distributions were similar before and after imputation.

To confirm the robustness of our findings, we performed several sensitivity analyses. First, we excluded patients with ILD or cancer from the analysis since rituximab is commonly used in these patients, who may also be susceptible to poor COVID-19 outcomes. Second, given data showing a strong association between race/ethnicity and COVID-19 outcomes in the USA, we performed an analysis adjusting for this variable among US patients in the registry. The race/ethnicity variable was categorised as white, black, Hispanic, Asian or other/mixed race. However, for the model with IL-6i, there were few outcomes within the race/ethnicity variable so we were unable to perform the model. Third, we used propensity score matching to further address potential confounding by indication. We estimated propensity scores for b/tsDMARD use based on age, sex, obesity, smoking, concomitant csDMARDs, glucocorticoid use/dose, number of comorbidities, disease activity, region and calendar time. Covariate balance between each b/tsDMARD drug class and TNFi was assessed using Love plots (online supplemental figures 1–4), which showed that most of the covariates were matched with an absolute standardised mean difference less than 0.1, denoting sufficient matching performance.[23] Ordinal logistic regression was then performed after matching. Fourth, we repeated our primary analysis after excluding patients with a presumptive diagnosis of COVID-19. Presumptive cases were those that lacked one of the following: positive PCR or antigen test for SARS-CoV-2 or typical chest imaging findings. Fifth, we repeated the analysis but stratified by calendar time (before or after 15 June 2020 when RECOVERY trial's results were announced) and by continent (North America or Europe) in case calendar time and geography may have influenced the results. Sixth, we used a revised version of the ordinal COVID-19 severity outcome that considered mechanical ventilation as its own category.

We then repeated our primary analyses using dichotomised outcomes rather than the ordinal COVID-19 severity scale to investigate whether there were particular outcomes driving the associations we observed. For example, we investigated whether each b/tsDMARD was associated with hospitalisation (yes/no) compared with TNFi use.

We used the Brant test to assess whether the observed deviations from the ordinal logistic regression are larger than what could be attributed to chance alone. If the p values are greater than the alpha level of 0.05, then the covariates satisfy the proportional odds assumption. This assumption states that the estimate between each pair of outcomes across the response levels regardless of the partition that we consider. For abatacept and JAKis, both age and glucocorticoid dose violated the assumption, and for IL-6is and rituximab, age, gender and glucocorticoid dose violated the assumption. In order to address the lack of proportionality for these covariates, partial proportional odds models were run to relax this assumption for the respective covariates for each medication category (online supplemental table 1). We found that the estimates were similar when comparing the proportional odds models and the non-proportional odds model, so we reported the model without relaxing the assumption.

Results were considered statistically significant at two-sided p<0.05. Analyses were conducted in R V.4.0.2.

RESULTS

Study sample and baseline characteristics

From a total of 6132 RA cases reported to the registry, we identified 2869 who were on abatacept (n=237), rituximab (n=364), IL-6i (n=317), JAKi (n=563) or TNFi (n=1388) at the time of clinical COVID-19 onset. The baseline clinical characteristics are shown in table 1. The sample was predominantly female (80.8%) and the mean age was 56.7 years (SD 13.4). Most patients were from Europe (51.8%) and North America (35.0%). Overall, 354 (12.3%) were obese, 582 (20.3%) were ever smokers, 810 (28.2%) were on glucocorticoids, 1409 (49.1%) were on concomitant csDMARDs, and 510 (17.8%) had moderate/high RA disease activity. Among b/tsDMARD users, rituximab users were more likely than TNFi users to have ILD (11.0% vs 1.4%) or a history of cancer (7.4% vs 0.9%); JAKi users were slightly more likely than TNFi users to be obese (15.1% vs 10.3%).

Rheumatoid arthritis

Table 1 Baseline characteristics according to use of biologic or targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis at the time of COVID-19 onset

	Overall N=2869	Abatacept n=237	Rituximab n=364	IL-6 inhibitors n=317	JAK inhibitors n=563	TNF inhibitors n=1388
Demographics						
Mean age (years), SD	56.7 (13.4)	61.4 (14.0)	58.0 (12.9)	56.4 (12.0)	58.0 (12.3)	55.2 (14.0)
Female	2316 (80.8)	188 (79.3)	299 (82.1)	257 (81.3)	470 (83.5)	1102 (79.4)
Race/ethnicity						
White	1670 (69.0)	78 (69.5)	187 (64.5)	169 (67.9)	360 (73.2)	829 (69.3)
Black	113 (4.7)	5 (3.2)	14 (4.8)	11 (4.4)	22 (4.5)	60 (5.0)
Hispanic	472 (19.5)	32 (20.8)	66 (22.8)	46 (18.5)	79 (16.1)	233 (19.5)
East Asian	81 (3.3)	8 (5.2)	10 (3.4)	12 (4.8)	10 (2.0)	37 (3.1)
Other	85 (3.3)	2 (1.3)	13 (4.5)	11 (4.4)	21 (4.3)	38 (3.2)
Continent						
Europe	1486 (51.8)	103 (43.5)	218 (59.9)	183 (57.7)	283 (50.3)	699 (50.4)
North America	1005 (35.0)	105 (44.3)	111 (30.5)	83 (26.2)	208 (36.9)	498 (35.9)
South America	276 (9.6)	20 (8.4)	23 (6.3)	33 (10.4)	55 (9.8)	145 (10.4)
Other	302 (10.5)	9 (3.8)	12 (3.3)	18 (5.7)	17 (3.0)	46 (3.3)
Comorbidity count*						
0	1494 (52.1)	113 (47.7)	161 (44.2)	161 (50.8)	270 (48.0)	789 (56.8)
1	837 (29.2)	70 (29.5)	119 (32.7)	99 (31.2)	176 (31.3)	373 (26.9)
2	538 (18.8)	54 (22.8)	84 (23.1)	57 (18.0)	117 (20.8)	226 (16.3)
Individual comorbidities						
Hypertension	983 (34.3)	91 (38.4)	121 (33.2)	108 (34.1)	221 (39.3)	442 (31.8)
Cardiovascular disease	247 (8.6)	29 (12.2)	36 (9.9)	32 (10.1)	51 (9.1)	99 (7.1)
Diabetes	356 (12.5)	30 (12.8)	54 (14.9)	43 (13.6)	74 (13.2)	155 (11.3)
Chronic kidney disease	98 (3.4)	11 (4.7)	11 (3.0)	14 (4.4)	22 (3.9)	40 (2.9)
Lung disease†	432 (15.2)	41 (17.4)	87 (24.0)	44 (13.9)	92 (16.4)	168 (12.3)
Interstitial lung disease	103 (3.6)	15 (6.3)	40 (11.0)	15 (4.7)	13 (2.3)	20 (1.4)
Cancer	40 (1.5)	5 (2.5)	27 (7.4)	6 (2.2)	5 (1.0)	11 (0.9)
Obesity	354 (12.3)	31 (13.1)	52 (14.3)	43 (13.6)	85 (15.1)	143 (10.3)
Smoking status						
Ever	582 (20.3)	104 (43.9)	70 (19.2)	57 (18.0)	99 (17.6)	300 (21.6)
Never	1369 (47.7)	56 (23.6)	142 (39.0)	152 (47.9)	262 (46.5)	694 (50.)
Missing	918 (32.0)	77 (32.5)	137 (37.6)	107 (33.8)	202 (35.9)	394 (28.4)
Concomitant RA medications						
Any conventional synthetic DMARD	1409 (49.1)	118 (49.8)	194 (53.3)	102 (32.2)	228 (40.5)	767 (55.3)
Methotrexate	1188 (41.4)	92 (38.8)	146 (40.1)	91 (28.7)	188 (33.4)	671 (48.3)
Sulfasalazine	136 (4.7)	9 (3.8)	26 (7.1)	8 (2.5)	18 (3.2)	75 (5.4)
Hydroxychloroquine	260 (9.1)	25 (10.5)	58 (15.9)	18 (5.7)	43 (7.6)	116 (8.4)
Leflunomide	176 (10.5)	26 (11.0)	49 (13.5)	20 (6.3)	29 (5.2)	117 (8.4)
Glucocorticoid dose, median (IQR)	5.0 (4.0–6.0)	5.0 (4.0–5.5)	5.0 (5.0–7.5)	5.0 (4.5–7.0)	5.0 (3.0–5.0)	5.0 (5.0–7.0)
Categorical glucocorticoid use/dose						
No glucocorticoid use	1756 (61.2)	120 (56.9)	186 (51.1)	173 (54.6)	320 (63.5)	957 (76.1)
Glucocorticoid >0–5 mg/day prednisone equivalent	600 (20.9)	68 (32.2)	93 (25.5)	69 (21.8)	149 (29.6)	221 (17.6)
Glucocorticoid 6–9 mg/day prednisone equivalent	68 (2.4)	8 (3.8)	10 (2.7)	15 (4.7)	12 (2.4)	23 (1.8)
Glucocorticoid ≥10 mg/day prednisone equivalent	142 (4.9)	15 (7.1)	28 (7.7)	19 (6.0)	23 (4.6)	57 (4.5)
Missing	303 (10.6)	26 (11.0)	47 (12.9)	41 (12.9)	59 (10.5)	130 (9.4)
RA disease activity by global physician assessment						
Remission or low	1949 (67.9)	147 (74.2)	226 (76.1)	198 (77.3)	388 (78.7)	990 (81.5)
Moderate or high	510 (17.8)	51 (25.8)	71 (23.9)	58 (22.7)	105 (21.3)	225 (18.5)
Missing	410 (14.3)	39 (16.5)	67 (18.4)	61 (19.2)	70 (12.4)	173 (12.5)
Confirmed COVID-19	2333 (81.3)	201 (84.8)	304 (83.5)	244 (77.0)	475 (84.4)	1109 (79.9)

n (%) presented unless otherwise specified.
*Comorbidity count included diabetes, lung disease and chronic kidney disease.
†Interstitial lung disease, chronic obstructive pulmonary disease, asthma or other lung disease.
DMARDs, disease-modifying antirheumatic drugs; IL-6, interleukin 6; JAK, Janus kinase; RA, rheumatoid arthritis; TNF, tumour necrosis factor.

COVID-19 outcomes

Outcomes according to the COVID-19 severity scale are shown in table 2. The majority of patients (78.6%) were not hospitalised, 137 (4.8%) were hospitalised without oxygenation, 319 (11.1%) were hospitalised with any oxygen or ventilation requirement, and 157 (5.5%) died. Among rituximab users, 80 (22.0%) required hospitalisation with any oxygen or ventilation and 54 (14.8%) died compared with 103 (7.4%)

Table 2 Frequencies and proportions of outcomes in the ordinal COVID-19 severity scale according to baseline use of biologic or targeted synthetic disease-modifying antirheumatic drug for patients with rheumatoid arthritis at the time of COVID-19 onset (N=2869)

COVID-19 severity scale	Overall N=2869 n (%)	Abatacept n=237 n (%)	Rituximab n=364 n (%)	IL-6 inhibitors n=317 n (%)	JAK inhibitors n=563 n (%)	TNF inhibitors n=1388 n (%)
Not hospitalised	2256 (78.6)	181 (76.4)	210 (57.7)	271 (85.5)	409 (72.6)	1185 (85.4)
Hospitalised without oxygenation	137 (4.8)	12 (5.1)	20 (5.5)	13 (4.1)	28 (5.0)	64 (4.6)
Hospitalised with any oxygen or ventilation	319 (11.1)	26 (11.0)	80 (22.0)	24 (7.6)	86 (15.3)	103 (7.4)
Death	157 (5.5)	18 (7.6)	54 (14.8)	9 (2.8)	40 (7.1)	36 (2.6)

IL-6, interleukin 6; JAK, Janus kinase; TNF, tumour necrosis factor.

and 36 (2.6%) TNFi users, respectively. Among JAKi users, 86 (15.3%) were hospitalised with oxygen/ventilation and 40 (7.1%) died. Only 9 (2.8%) patients on baseline IL-6i died.

Associations of b/tsDMARDs with COVID-19 severity

The multivariable ordinal logistic regression model is shown in table 3. Compared with TNFi users, rituximab users had 4.15 (95% CI 3.40 to 3.80) greater odds of worse COVID-19 severity as compared with patients taking TNFi, while JAKi users had 2.06 (95% CI 1.60 to 2.65) greater odds of worse COVID-19 severity. No significant associations were found with respect to abatacept or IL-6i compared with TNFi in the primary analysis.

Sensitivity analyses

Sensitivity analyses of the drug class comparisons are shown in table 3. After excluding patients with ILD or cancer, the association between rituximab with poor COVID-19 outcomes when compared with TNFi use remained strong (OR 4.34, 95% CI 3.23 to 5.82). Among patients with RA in the USA, results were also similar when additionally adjusting for race/ethnicity. We also performed a propensity score-matched analysis instead of multivariable ordinal logistic regression. The sample for each propensity score-matched analysis is illustrated in online supplemental figure 5. Rituximab users (OR 3.36, 95% CI 2.11 to 5.34) and JAKi users (OR 1.56, 95% CI 1.01 to 2.42) had increased COVID-19 severity compared with TNFi users in this analysis. In the propensity score-matched analysis, abatacept had an OR of 1.60 (95% CI 1.02 to 2.51) for the ordinal COVID-19 severity outcome compared with TNFi. IL-6i use was not associated with COVID-19 severity in any of the analyses. Brant tests indicated that the proportional odds assumption did not hold for propensity score models; therefore, partial proportional odds models were used and confirmed that the effect estimates remained consistent (data not shown).

When stratified by calendar time (before or after 15 June 2020) and restricted to Europe or North America, the results were similar (online supplemental table 2).

Individual COVID-19 outcomes

We also performed analyses for each binary level of the COVID-19 severity scale (table 4). Rituximab and JAKi use were each associated with increased odds for each COVID-19 outcome compared with TNFi use. For example, rituximab use had increased odds for hospitalisation (OR 4.53, 95% CI 3.32 to 6.18) as well as death (OR 4.57, 95% CI 3.32 to 9.01) compared with TNFi use. JAKi use was associated with all outcomes considered, including hospitalisation requiring any oxygen or ventilation or death (OR 1.55, 95% CI 1.04 to 2.18) and death (OR 2.04, 95% CI 1.58 to 2.65) compared with TNFi. In these analyses, there were no statistically significant associations between

abatacept or IL-6i use and the dichotomised outcomes when compared with TNFi use.

We considered a revised version of the ordinal outcome that included mechanical ventilation as a separate level. There were relatively few patients who survived after requiring mechanical ventilation (online supplemental table 2). Results were similar using this revised ordinal outcome (online supplemental tables 3 and 4).

DISCUSSION

Among patients with RA on b/tsDMARDs at the onset of COVID-19, rituximab and JAKi users were at increased odds for worse COVID-19 outcomes compared with TNFi users. In contrast, we did not find an association between abatacept or IL-6i use with worse COVID-19 outcomes when compared with TNFi users. These observations can inform decision making for providers and patients during the ongoing COVID-19 pandemic. Given the association between rituximab and JAKi use with poor outcomes, vaccination and public health measures such as mask wearing and social distancing for COVID-19 risk mitigation remain paramount. In addition, other specific interventions (eg, monoclonal antibody treatment) might be considered in these patients with COVID-19 exposure or early infection.[24]

Our observations, which use the largest sample of individuals with RA and COVID-19 assembled to date, regarding rituximab exposure confirm findings from prior studies suggesting an association between baseline use of B cell depleting therapies and worse COVID-19 outcomes in people with rheumatic diseases[12 25 26] and multiple sclerosis.[27] We also expand on prior observations using the C19-GRA and EULAR databases by evaluating the association of rituximab with COVID-19 severity rather than only mortality and by using an alternative reference group (TNFi rather than methotrexate) and performing propensity score analyses to further address confounding by indication. By focusing on a single disease, we also were able to identify a novel association of JAKis with COVID-19 severity. Mechanistically, the impact of B cell depletion on antibody production would be expected to impair the immune system's normal response to a viral infection. Indeed, the antibody response to COVID-19 is critical for controlling the initial infection and preventing reinfection.[28] We lacked details regarding the timing of rituximab exposure in relation to the COVID-19 infection or the duration of B cell depletion at the time of infection, which may be particularly relevant when considering the risk of a poor outcome following rituximab exposure. It is also possible that glucocorticoids given as a premedication to rituximab infusions may have contributed to the increased risk of poor COVID-19 outcomes in patients with RA on rituximab. While the results were robust to several sensitivity analyses, it is possible that the result could be confounded by factors such as unrecognised ILD.

Table 3 Results of primary and sensitivity analyses investigating the associations of baseline use of biologic or targeted synthetic disease-modifying antirheumatic drugs with COVID-19 severity (N=2869)

	Abatacept		Rituximab		IL-6i		JAKi		TNFi
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	
Unadjusted	1.88 (1.35 to 2.63)	<0.01	4.63 (3.60 to 5.96)	<0.01	1.00 (0.71 to 1.41)	0.99	2.28 (1.80 to 2.88)	<0.01	Ref
Age-adjusted and sex-adjusted	1.40 (0.99 to 1.99)	0.06	4.45 (3.43 to 5.77)	<0.01	1.06 (0.68 to 1.37)	0.84	2.10 (1.64 to 2.68)	<0.01	Ref
Multivariable-adjusted (primary analysis)	1.26 (0.88 to 1.80)	0.21	4.15 (3.16 to 5.44)	<0.01	0.81 (0.56 to 1.18)	0.55	2.06 (1.60 to 2.65)	<0.01	Ref
Confirmed cases only*	1.14 (0.77 to 1.68)	0.52	4.25 (3.17 to 5.69)	<0.01	0.74 (0.49 to 1.11)	0.15	2.05 (1.57 to 2.69)	<0.01	Ref
Excluding patients with ILD or cancer†	1.18 (0.79 to 1.76)	0.43	4.34 (3.23 to 5.82)	<0.01	0.81 (0.54 to 1.21)	0.30	2.14 (1.64 to 2.79)	<0.01	Ref
Restricted to USA and additionally adjusted for race‡	1.16 (0.79 to 1.69)	0.45	4.77 (3.57 to 6.38)	<0.01†	¶	¶	2.86 (1.76 to 4.65)	<0.01†	Ref
Propensity score-matched§	1.60 (1.02 to 2.51)	0.04	4.70 (3.31 to 6.65)	<0.01	0.76 (0.46 to 1.23)	0.26	2.09 (1.50 to 2.90)	<0.01	Ref

The effect size is the odds of being one level higher on the ordinal COVID-19 severity scale than the reference group (TNFi users).
Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer and rheumatoid arthritis disease activity except as otherwise indicated.
*n=2333 in the analysis analysing only confirmed COVID-19 cases.
†n=2704 in the analysis excluding ILD and cancer.
‡n=868 in the USA-only analysis.
§n for each pair of propensity score-matched analyses: abatacept: 236, TNFi: 1376; rituximab: 364, TNFi: 1382; IL-6i: 313, TNFi: 1387; JAKi: 560, TNFi: 1379.
¶Due to the small number of events in the covariate of race, the IL-6i model could not be analysed.
csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ILD, interstitial lung disease; IL6i, interleukin 6 inhibitor; JAKi, Janus kinase inhibitor; Ref, reference; TNFi, tumour necrosis factor inhibitors.

Table 4 Multivariable* OR of biologic or targeted synthetic disease-modifying antirheumatic drugs at each binary level of the COVID-19 severity scale (N=2869)

COVID-19 outcome	Abatacept		Rituximab		IL-6 inhibitors		JAK inhibitors		TNF inhibitors
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	
Hospitalised	1.18 (0.76 to 1.82)	0.47	4.53 (3.32 to 6.18)	<0.01	0.84 (0.53 to 1.33)	0.45	2.40 (1.78 to 3.24)	<0.01	Ref
Hospitalised with oxygenation/ventilation or death	1.12 (0.70 to 1.81)	0.63	2.87 (2.03 to 4.06)	<0.01	0.72 (0.43 to 1.20)	0.20	1.55 (1.04 to 2.18)	0.01	Ref
Death	1.46 (0.72 to 2.89)	0.30	4.57 (3.32 to 9.01)	<0.01	1.13 (0.50 to 2.59)	0.77	2.04 (1.58 to 2.65)	<0.01	Ref
Mechanical ventilation (restricted to only hospitalised patients, n=613)	1.41 (0.94 to 2.10)	0.09	4.05 (3.08 to 5.33)	<0.01	0.75 (0.51 to 1.10)	0.14	2.03 (1.56 to 2.62)	<0.01	Ref
Mechanical ventilation or death	1.14 (0.78 to 1.66)	0.50	4.44 (3.39 to 5.82)	<0.01	0.74 (0.50 to 1.09)	0.12	2.02 (1.56 to 2.61)	<0.01	Ref

*Adjusted for age, sex, region, calendar time, obesity, smoking, concomitant csDMARD use, glucocorticoid use/dose, comorbidity count, hypertension/cardiovascular disease, interstitial lung disease, cancer and rheumatoid arthritis disease activity.
csDMARD, conventional synthetic disease-modifying antirheumatic drug; IL-6, interleukin 6; JAK, Janus kinase; Ref, reference; TNF, tumour necrosis factor.

Our findings are of particular interest given recent clinical trials and observational studies suggesting that IL-6i[6–8 29–32] and JAKi[9] may improve outcomes for patients in the general population with COVID-19. We found no association of baseline IL-6i use in RA with COVID-19 severity compared with TNFi use. In contrast, while baricitinib treatment may have some benefit on time to recovery for patients with more severe COVID-19,[9] we observed worse outcomes associated with baseline use of JAKi. This was also suggested in a recent population-based study investigating RA and other inflammatory joint diseases in Sweden.[25] Glucocorticoids are known to have benefits when initiated for moderate-to-severe COVID-19, but are also associated with worse outcomes among those on baseline glucocorticoids at the time of infection,[5 12] although this may be explained by residual disease activity.[33] Therefore, the timing of JAKi use relative to the COVID-19 disease course may explain our findings. Similar to glucocorticoids, baseline use of JAKi at the time of SARS-CoV-2 infection may enhance viral reproduction and dampen a healthy immune response, while JAKi initiation at clinical deterioration may dampen an aberrant systemic inflammatory response. Alternatively, there may be relevant differences in COVID-19 outcomes depending on the type of JAKi used given that JAKis like tofacitinib, baricitinib and upadacitinib target different Janus kinases. We were unable to perform analyses of each individual JAKi since these were collected as a class. While the primary analysis found no association of abatacept with COVID-19 severity, there was a statistical association in the propensity score-matched analysis. Further research is needed on the safety of abatacept for infection risk and severity since its mechanism of action may impair adaptive immune response.

Our study has a number of strengths, including the international nature of the registry and the large sample size. Additionally, we used an active comparator (TNFi), which was also a b/tsDMARD in a single rheumatic disease, as well as two different modelling approaches (multivariable logistic regression and propensity score matching) among other sensitivity analyses to account for confounding by indication and to confirm the robustness of our findings. Our observations expand on prior general population and RA cohort studies that identified older age, greater comorbidity burden and other factors associated with worse COVID-19 and must also be considered when assessing an individual's risk.

Our study also has certain limitations. First, the Global Rheumatology Alliance and EULAR registries are voluntary and require a provider to submit the details of a case, perhaps biasing our sample towards more severe cases. As such, the proportion of events reported across exposure groups may be an overestimate of that observed among all patients with RA in real-world practice and should be interpreted in that context. However, the effect size estimates do have clinical interpretation in potentially identifying patients with RA who could be susceptible to poor COVID-19 outcomes. While we designed the study to limit the potential impact of selection bias and confounding by indication by examining advanced therapies in a single rheumatic disease, it is possible that selective reporting could have varied across different b/tsDMARD classes as the exposure of interest. This potential bias may have caused an upward deflection in the effect size estimate if more severe cases of a particular b/tsDMARD class were systematically reported compared with others, and this could contribute to the findings that we report. We further mitigated this possibility by adjusting for differences in concomitant medication use, disease activity and comorbidities, as well as performing an analysis removing patients with ILD or cancer. Our findings remained when we excluded presumptive cases of COVID-19. Second, although we were able to adjust for a number of potential confounders of our observed associations, there is the potential for residual unmeasured confounding. Analysing only patients on b/tsDMARD may have helped minimise some unmeasured confounding related to access to care since all analysed patients with RA were able to receive these targeted medications. In addition, the consistent results observed in sensitivity analyses excluding patients with ILD or cancer who may be more likely to receive rituximab support the robustness of our results. However, we did not have data available on RA duration or previous RA medications (eg, previous TNFi use in patients on other classes of b/tsDMARDs), which may have affected the results. Medications were collected by DMARD class, so we were unable to compare individual medications within the same class. However, the goal of the study was to compare different biologic mechanisms of action for COVID-19 severity. Additionally, it is also possible that TNFi use may protect against severe COVID-19 outcomes. Thus, these results should be interpreted cautiously and additional studies are needed to confirm our observed associations. Third, while we leveraged the largest cohort of patients with rheumatic disease with COVID-19, a somewhat small number of outcomes of interest occurred in some subgroups, which may have limited our power to detect significant differences among abatacept users, in particular. In addition, we were unable to investigate individual JAKi or TNFi. Finally, we did not examine medication changes after COVID-19 onset since this occurred after baseline and may have mediated the relationship we report. Most of the drugs have lengthy biologic effects (especially rituximab), while JAKis have short half-lives. Some clinicians may have chosen to continue IL-6is after COVID-19 onset, as suggested by the American College of Rheumatology.[34] Future studies are needed to investigate the association of medication changes with COVID-19 outcomes.

In conclusion, use of rituximab or JAKi, but not abatacept or IL-6i, at the time of COVID-19 infection was associated with worse COVID-19 outcomes compared with TNFi among patients with RA. Additional studies are warranted to confirm these observations. Strategies are needed to improve outcomes following COVID-19 RA on rituximab or JAKis.

Author affiliations
[1]Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA
[2]Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
[3]Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA
[4]Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA
[5]Division of Rheumatology, Department of Medicine, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
[6]Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
[7]National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
[8]Epidemiology and Health Care Research, German Rheumatism Research Center Berlin, Berlin, Germany
[9]INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France
[10]APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France
[11]Instituto de Salud Musculoesqueletica, Madrid, Spain
[12]Portuguese League Against Rheumatic Diseases, Lisbon, Portugal
[13]Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), European League Against Rheumatism, Kilchberg, Switzerland

[14]Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK

[15]National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK

[16]San Francisco VA Health Care System, San Francisco, California, USA

[17]Department of Internal Medicine, Division of Rheumatology, University of Southern California, Los Angeles, California, USA

[18]Division of Rheumatology, Mayo Clinic Hospital Jacksonville, Jacksonville, Florida, USA

[19]Division of Rheumatology, Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic Rochester, Rochester, Minnesota, USA

[20]Division of Rheumatology, Mayo Clinic Rochester, Rochester, Minnesota, USA

[21]SAR-COVID, Argentina Society of Rheumatology, Buenos Aires, Argentina

[22]Rheumatology, Sanatorio Britanico Rosario, Buenos Aires, Argentina

[23]Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA

[24]Hospital Universitário Getúlio Vargas, Faculty of Medicine, Federal University of Amazonas, Manaus, Amazonas, Brazil

[25]Rheumatology Department, Hamad Medical Corporation, Doha, Qatar

[26]Division of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

[27]Epidemiology Research Unit, Italian Society of Rheumatology, Milano, Italy

[28]Department of Rheumatology, Central Hospital of Bolzano, Padua, Italy

[29]Société Française de Rhumatologie (SFR), Department of Rheumatology, Hôpital Nord, Universite de Lyon, Lyon, France

[30]Department of Rheumatology, University of Lille, Lille, France

[31]Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Universite de Paris, Paris, France

[32]Department of Rheumatology, Assistance Publique, Hopitaux de Paris, Universite Paris-Saclay, Saint-Aubin, France

[33]Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal

[34]Rheumatology Department, Centro Hospitalar de Sao Joao EPE, Porto, Portugal

[35]Rheumatology Department, Garcia de Orta Hospital, Almada, Portugal

[36]Division of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig Universitat Giessen, Giessen, Germany

[37]Division of Rheumatology and Clinical Immunology, Internal Medicine IV, Ludwig-Maximilians-Universitat Munchen, Munchen, Germany

[38]Department of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte, Essen, Germany

[39]Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil

[40]Hospital Universitário de Brasilia, Universidade de Brasilia, Brasilia, Federal District, Brazil

[41]Centro Universitario de Brasilia, Brasilia, Federal District, Brazil

[42]Rheumatology Department, Bichat-Claude Bernard Hospital, Paris University, Paris, France

[43]Centre for Rheumatic Diseases, King's College Hospital, King's College London, London, UK

[44]Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA

[45]Division of Rheumatology, University of Washington, Seattle, Washington, USA

[46]School of Medicine, Universidad Cientifica del Sur, Lima, Peru

[47]Rheumatology Department, Level IV Hospital Guillermo Almenara Irigoyen, La Victoria, Peru

[48]Department of Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, Michigan, USA

[49]VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA

[50]Rheumatology Department, Royal Hallamshire Hospital, Sheffield, UK

[51]UQ Diamantina Institute, The University of Queensland, Saint Lucia, Queensland, Australia

[52]Crystal Run Healthcare, Middletown, New York, USA

[53]Irish Children's Arthritis Network (iCan), Tipperary, Ireland

[54]Department of Medicine, University of Otago, Dunedin, New Zealand

[55]Program in Rheumatology, Boston Children's Hospital, Boston, Massachusetts, USA

[56]Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

[57]Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA

[58]Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada

[59]Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada

[60]HealthPartners, St. Paul, Minnesota, USA

[61]Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia

[62]Metro North Hospital and Health Service, Royal Brisbane and Women's Hospital Health Service District, Herston, Queensland, Australia

[63]Centre for Rheumatology and Department of Neuromuscular Diseases, University College London, London, UK

[64]National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK

Zlnay, Dagmar Mičeková (National Institute of Rheumatic Diseases, Piešťany, Slovak Republic), Lubica Capova (University Hospital, Bratislava, Slovak Republic), Zelmira Macejova (University Hospital, Košice, Slovak Republic), Emőke Šteňová (University Hospital Bratislava, Slovak Republic), Helena Raffayova (National Institute of Rheumatic Diseases, Piešťany, Slovak Republic), Gabriela Belakova (Medman s.r.o., Martin, Slovak Republic), Eva Strakova (Faculty hospital Prešov, Slovak Republic), Marieta Senčarová (Louis Pasteur University Hospital, Košice, Slovak Republic), Soňa Žlnayová (Poliklinika MarMedico, s.r.o., Nové Mesto nad Váhom Slovak Republic súkromná reumatologická ambulancia, Vranov nad, Slovak Republic), Anna Sabová (Topľou, Slovak Republic), Daniela Spisakova (University Hospital od L. Pasteur Kosice, Slovak Republic), Mária Oetterová (Safarik University hospital, Kosice, Slovak Republic), Olga Lukacova (National Institute of Rheumatic Diseases, Piešťany, Slovak Republic), Martina Bakosova (UNB Nemocnica Stare Mesto, Bratislava, Slovak Republic), Alojzija Hocevar (UMC Ljubljana, Slovenia), Natalia de la Torre-Rubio (Hospital Universitario Puerta de Hierro Majadahonda, Spain), Juan José Alegre Sancho (Hospital Universitari Dr Peset, Valencia, Spain), Montserrat Corteguera Coro (Complejo Asistencial Avila, Spain), Juan Carlos Cobeta Garcia (Hospital Ernest Lluch, Calatayud, Spain), Maria Carmen Torres Martin (Hospital Nuestra Senora Sonsoles, Avila, Spain), Jose Campos (Hospital Universitario Puerta de Hierro, Spain), Jose A Gomez Puerta (Hospital Clinic Barcelona, Spain), Gozd Kubra Yardımcı, Servet Akar (Hacettepe University Faculty of Medicine, Ankara, Izmir Katip Celebi University Atatürk Training and Research Hospital, Izmir, Turkey), Ozan Cemal Icacan (Bakırköy Dr. Sadi Konuk Research And Training Hospital, Istanbul, Turkey), Selda ÇELİK (Bakirkoy Dr Sadi Konuk Educational And Research Hospital, Rheumatology Department, Turkey), Viktoriia Vasylets (Multifield Medical Centre, Odessa, Ukraine), Su-Ann Yeoh (University College London Hospital, London, UK), Claire Vandevelde (Leeds Teaching Hospitals NHS Trust, UK), Sasha Dunt (Countess of Chester NHS Foundation Trust, UK), Jane Leeder (Norfolk & Norwich University Hospital, UK), Elizabeth Macphie (Lancashire and South Cumbria NHS Foundation Trust, UK), Rosaria Salerno (King's College Hospital, UK), Christine Graver (Hampshire Hospitals NHS Trust, UK), Katie Williams (York District Hospital, UK), Sheila O'Reilly (Royal Derby Hospital, UK), Kirsty Devine (York/Scarborough Hospitals, UK), Jennifer Tyler (Royal United Hospital, Bath, UK), Elizabeth Warner (Lister Hospital, UK), James Pilcher (University Hospital Lewisham, UK), Samir Patel (Queen Elizabeth hospital Woolwich, UK), Elena Nikiphorou (King's College Hospital, UK), Laura Chadwick (St Helens & Knowsley NHS Foundation Trust, UK), Caroline Mulvaney Jones (Llandudno Hospital, UK), Beverley Harrison (Salford Royal NHS FT, UK), Lucy Thornton (Bradford Royal Infirmary, UK), Diana O'Kane (RNHRD at Royal United Hospital Bath, UK), Lucia Fusi (King's College Hospital, UK), Audrey Low (Salford Royal NHS FT, UK), Sarah Horton (Minerva Health Centre, UK), Shraddha Jatwani (Albert Einstein Medical Center, PA, USA), Sara Baig, Hammad Bajwa, Vernon Berglund, Angela Dahle, Walter Dorman, Jody Hargrove, Maren Hilton, Nicholas Lebedoff, Susan Leonard, Jennifer Morgan, Emily Pfeifer, Archibald Skemp, Jeffrey Wilson, Anne Wolff (Arthritis and Rheumatology Consultants, PA, USA), Eduardo Cepeda (Austin Diagnostic Clinic, USA), Derrick Todd (Brigham and Women's Hospital, USA), Denise Hare (Capital Health Rheumatology, USA), Cassandra Calabrese (Cleveland Clinic, USA), Christopher Adams (East Alabama Medical Center, USA), Arezou Khosroshahi (Emory University, USA), Adam Kilian (George Washington University, USA), Douglas White, Melanie Winter (Gundersen Health System, USA), Theodore Fields (Hospital for Special Surgery, USA), Caroline Siegel (Hospital for Special Surgery, USA), Nicole Daver (Institute of Rheumatic and Autoimmune Diseases, USA), Melissa Harvey (Institute of Rheumatic and Autoimmune Diseases, USA), Neil Kramer (Institute of Rheumatic and Autoimmune Diseases, USA), Concetta Lamore (Institute of Rheumatic and Autoimmune Diseases, USA), Suneya Hogarty (Integrative Arthritis and Pain Consultants, USA), Karen Yeter (Kaiser Permanente, USA), Leanna Wise (Los Angeles County + USC Medical Center, USA), Faizah Siddique (Loyola University Medical Center, USA), Byung Ban (Medstar Georgetown University Hospital, USA), Tamar Tanner (Montefiore Medical Center, USA), Eric Ruderman (Northwestern Memorial, USA), William Davis, Robert Quinet, Evangeline Scopelitis, Karen Toribio Toribio, Tameka Webb-Detiege, Jerald Zakem (Ochsner Medical Center Rheumatology Department, USA), Khurram Abbass, Gilbert Kepecs (Private Practice, USA), Lilliam Miranda (Rheumatology Center INC, USA), Michael Guma, Ammar Haikal, Sushama Mody (Riverside Medical Group, USA), Daric Mueller (Shores Rheumatology PC, USA), Arundathi Jayatilleke (Temple University Hospital, USA), JoAnn Zell (University of Colorado, USA), Alison Bays (University of Washington, Seattle, USA), Kathryn Dao, Ezzati Fatemeh (UT Southwestern Medical Center, USA), Deborah Parks (Washington University Div of Rheumatology, USA), David Karp, Guillermo Quiceno (UT Southwestern Medical Center, USA).

Contributors JAS, ZSW, AS, MG and JY had access to the study data, developed the figures and tables, and vouch for the data and analyses. AS and MG performed the statistical analyses and contributed to data quality control, data analysis and interpretation of data. JAS, ZSW, AMS, MG, ZI, KLH, AS, LG, LC, EFM, SL-T, LT, SR, PK, GS, LJ, SAE, LW, ELG, AD-G, MOV-A, GJP-E, CAI, GAB, TY-TH, KMD'S, NJP, PD, EN, VLK, NS, MFU-G, BW, AA, RT, SB, WC, RG, JH, JL, ES, PS, PCR, PMM and JY contributed to data collection, data analysis and interpretation of data. JAS, ZSW and JY directed the work, designed the data collection methods, contributed to data collection, data analysis and interpretation of data, and had final responsibility for

the decision to submit for publication. All authors contributed intellectual content during the drafting and revision of the work and approved the final version to be published.

Disclaimer The views expressed here are those of the authors and the participating members of the COVID-19 Global Rheumatology Alliance and do not necessarily represent the views of the American College of Rheumatology (ACR), the European Alliance of Associations for Rheumatology (EULAR), the (UK) National Health Service (NHS), the National Institute for Health Research (NIHR) or the (UK) Department of Health, or any other organisation.

Competing interests JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253 and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R Bruce and Joan M Mickey Research Scholar Fund. JAS has received research support from Amgen and Bristol-Myers Squibb and performed consultancy for Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum, unrelated to this work. ZSW reports grant support from Bristol-Myers Squibb and Principia/Sanofi and performed consultancy for Viela Bio and MedPace, outside the submitted work. His work is supported by grants from the National Institutes of Health. MG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534; JY). KLH reports she has received speaker's fees from AbbVie and grant income from BMS, UCB and Pfizer, all unrelated to this study. KLH is also supported by the NIHR Manchester Biomedical Research Centre. LC has not received fees or personal grants from any laboratory, but her institute works by contract for laboratories such as, among other institutions, AbbVie Spain, Eisai, Gebro Pharma, Merck Sharp & Dohme España, Novartis Farmaceutica, Pfizer, Roche Farma, Sanofi Aventis, Astellas Pharma, Actelion Pharmaceuticals España, Grünenthal and UCB Pharma. LG reports research grants from Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz and Sanofi; consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi Aventis and UCB, all unrelated to this study. EFM reports that LPCDR received support for specific activities: grants from AbbVie, Novartis, Janssen-Cilag, Lilly Portugal, Sanofi, Grünenthal, MSD, Celgene, Medac, Pharma Kern and GAfPA; grants and non-financial support from Pfizer; and non-financial support from Grünenthal, outside the submitted work. AS reports grants from a consortium of 13 companies (among them AbbVie, BMS, Celltrion, Fresenius Kabi, Lilly, Mylan, Hexal, MSD, Pfizer, Roche, Samsung, Sanofi Aventis and UCB) supporting the German RABBIT register, and personal fees from lectures for AbbVie, MSD, Roche, BMS and Pfizer, outside the submitted work. AD-G has no disclosures relevant to this study. His work is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation. KMD is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258) and the Rheumatology Research Foundation. NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258). PD has received research support from Bristol-Myers Squibb, Chugai and Pfizer, and performed consultancy for Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Sanofi, Pfizer, Chugai, Roche and Janssen, unrelated to this work. NS is supported by the RRF Investigator Award and the American Heart Association. MFU-G reports grant support from Janssen and Pfizer. SB reports no competing interests related to this work. He reports non-branded consulting fees for AbbVie, Horizon, Novartis and Pfizer (all <$10 000). RG reports no competing interests related to this work. Outside of this work she reports personal and/or speaking fees from AbbVie, Janssen, Novartis, Pfizer and Cornerstones, and travel assistance from Pfizer (all <$10 000). JH reports no competing interests related to this work. He is supported by grants from the Rheumatology Research Foundation and the Childhood Arthritis and Rheumatology Research Alliance. He has performed consulting for Novartis, Sobi and Biogen, all unrelated to this work (<$10 000). JL has received research funding from Pfizer, outside the submitted work. ES is a Board Member of the Canadian Arthritis Patient Alliance, a patient-run, volunteer-based organisation whose activities are largely supported by independent grants from pharmaceutical companies. PS reports no competing interests related to this work. He reports honorarium for doing social media for American College of Rheumatology journals (<$10 000). PMM has received consulting/speaker's fees from AbbVie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche and UCB, all unrelated to this study (all <$10 000). PMM is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). PCR reports no competing interests related to this work. Outside of this work he reports personal consulting and/or speaking fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB, and travel assistance from Roche (all <$10 000). JY reports no competing interests related to this work. Her work is supported by grants from the National Institutes of Health, Centers for Disease Control, and the Agency for Healthcare Research and Quality. She has performed consulting for Eli Lilly and AstraZeneca, unrelated to this project.

Patient consent for publication Not required.

ORCID iDs
Jeffrey A Sparks http://orcid.org/0000-0002-5556-4618
Kimme L Hyrich http://orcid.org/0000-0001-8242-9262
Anja Strangfeld http://orcid.org/0000-0002-6233-022X
Laure Gossec http://orcid.org/0000-0002-4528-310X
Loreto Carmona http://orcid.org/0000-0002-4401-2551
Saskia Lawson-Tovey http://orcid.org/0000-0002-8611-162X
Ali Duarte-García http://orcid.org/0000-0003-1749-5719
Guillermo J Pons-Estel http://orcid.org/0000-0002-0647-929X
Tiffany Y -T Hsu http://orcid.org/0000-0003-1041-8040
Kristin M D'Silva http://orcid.org/0000-0001-8370-4166
Lianne Kearsley-Fleet http://orcid.org/0000-0003-0377-1575
Sandra Lúcia Euzébio Ribeiro http://orcid.org/0000-0002-4777-8659
Carlo Alberto Scirè http://orcid.org/0000-0001-7451-0271
Rebecca Hasseli http://orcid.org/0000-0002-2982-8253
Hendrik Schulze-Koops http://orcid.org/0000-0002-1681-491X
Christof Specker http://orcid.org/0000-0003-2504-3229
Licia Maria Henrique da Mota http://orcid.org/0000-0002-8182-5121
Ana Paula Monteiro Gomides http://orcid.org/0000-0003-2884-2210
Philippe Dieudé http://orcid.org/0000-0002-4814-0307
Elena Nikiphorou http://orcid.org/0000-0001-6847-3726
Vanessa L Kronzer http://orcid.org/0000-0002-7489-3134
Namrata Singh http://orcid.org/0000-0001-7149-363X
Manuel F Ugarte-Gil http://orcid.org/0000-0003-1728-1999
Akpabio Akpabio http://orcid.org/0000-0002-4920-6494
Ranjeny Thomas http://orcid.org/0000-0002-0518-8386
Jonathan S Hausmann http://orcid.org/0000-0003-0786-8788
Emily Sirotich http://orcid.org/0000-0002-7087-8543
Philip C Robinson http://orcid.org/0000-0002-3156-3418
Pedro M Machado http://orcid.org/0000-0002-8411-7972

REFERENCES

1 D'Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. *Curr Opin Rheumatol* 2021;33:255–61.
2 Antony A, Connelly K, De Silva T, et al. Perspectives of patients with rheumatic diseases in the early phase of COVID-19. *Arthritis Care Res* 2020;72:1189–95.
3 Ma MHY, Tay SH, Cheung PPM, et al. Attitudes and behaviors of patients with rheumatic diseases during the early stages of the COVID-19 outbreak. *J Rheumatol* 2021;48:35–9.
4 George MD, Venkatachalam S, Banerjee S, et al. Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic. *J Rheumatol* 202010.3899/jrheum.201017. [Epub ahead of print: 15 Nov 2020].
5 Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. *Ann Rheum Dis* 2020;79:859–66.
6 , Gordon AC, Mouncey PR, et al, REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. *N Engl J Med* 2021;384:1491–502.
7 Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. *N Engl J Med* 2021;384:20–30.
8 Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. *JAMA Intern Med* 2021;181:41–51.
9 Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. *N Engl J Med* 2021;384:795–807.
10 Tavakolpour S, Alesaeidi S, Darvishi M, et al. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. *Clin Rheumatol* 2019;38:2977–94.
11 Selmi C, Ceribelli A, Naguwa SM, et al. Safety issues and concerns of new immunomodulators in rheumatology. *Expert Opin Drug Saf* 2015;14:389–99.
12 Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. *Ann Rheum Dis* 2021:annrheumdis-2020-219498.
13 Robinson PC, Yazdany J, Machado PM. Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 global rheumatology alliance. *Curr Opin Rheumatol* 2021;33:111–6.
14 Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 global rheumatology alliance physician registry. *Arthritis Rheumatol* 2021;73:374–80.
15 Liew JW, Bhana S, Costello W, et al. The COVID-19 global rheumatology alliance: evaluating the rapid design and implementation of an international registry against best practice. *Rheumatology* 2021;60:353–8.
16 Wallace ZS, Bhana S, Hausmann JS, et al. The rheumatology community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. *Rheumatology* 2020;59:1204–6.
17 Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. *Lancet Rheumatol* 2020;2:e250–3.
18 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020;383:1813–26.
19 Brant R. Assessing proportionality in the proportional odds model for ordinal logistic regression. *Biometrics* 1990;46:1171–8.
20 Williams R. Generalized ordered Logit/Partial proportional odds models for ordinal dependent variables. *Stata J* 2006;6:58–82.
21 Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and COX regression. *Am J Epidemiol* 2007;165:710–8.
22 RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med* 2021;384:693–704.
23 Zhang Z, Kim HJ, Lonjon G, et al. Balance diagnostics after propensity score matching. *Ann Transl Med* 2019;7:16.
24 ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. *N Engl J Med* 2021;384:905–14.
25 Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. *Ann Rheum Dis* 2021. doi:10.1136/annrheumdis-2021-219845. [Epub ahead of print: 23 Feb 2021].
26 Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. *Lancet Rheumatol* 2021. doi:10.1016/S2665-9913(21)00059-X. [Epub ahead of print: 25 Mar 2021].
27 Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. *Ann Neurol* 2021;89:780–9.
28 Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. *N Engl J Med* 2021;384:533–40.
29 Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. *N Engl J Med* 2021;384:1503–16.
30 Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med* 2020;383:2333–44.
31 Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. *JAMA Intern Med* 2021;181:32–40.
32 Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. *JAMA Intern Med* 2021;181:24–31.
33 Schäfer M, Strangfeld A, Hyrich KL, et al. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al. *Ann Rheum Dis* 2021. doi:10.1136/annrheumdis-2021-220134. [Epub ahead of print: 01 Mar 2021].
34 Mikuls TR, Johnson SR, Fraenkel L, et al. American College of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. *Arthritis Rheumatol* 2021;73:e1–12.